Postoperative Adjuvant Chemotherapy Improves Survival in Stage II Colon Cancer ? A Propensity Score Matching Analysis
Objective: The use of postoperative adjuvant chemotherapy (POAC) after surgery for patients with stage II colon cancer remains controversial. The current study was conducted to investigate the effectiveness of POAC using propensity score (PS) matching analysis based on prognostic factors.Materials:...
Gespeichert in:
Veröffentlicht in: | Juntendo Iji Zasshi = Juntendo Medical Journal 2016, Vol.62(6), pp.463-471 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 471 |
---|---|
container_issue | 6 |
container_start_page | 463 |
container_title | Juntendo Iji Zasshi = Juntendo Medical Journal |
container_volume | 62 |
creator | SUGIMOTO, KIICHI SAKAMOTO, KAZUHIRO NIWA, KOICHIRO ISHIYAMA, SHUN KAMIYAMA, HIROHIKO KOMIYAMA, HIROMITSU TAKAHASHI, MAKOTO KOJIMA, YUTAKA GOTO, MICHITOSHI TOMIKI, YUICHI |
description | Objective: The use of postoperative adjuvant chemotherapy (POAC) after surgery for patients with stage II colon cancer remains controversial. The current study was conducted to investigate the effectiveness of POAC using propensity score (PS) matching analysis based on prognostic factors.Materials: Two hundred and nineteen patients with stage II colon cancer who underwent surgery with curative intent between 1995 and 2005 were enrolled.Methods: PS matching analysis was used to adjust for differences in clinicopathological severity between the patients with and without POAC.Results: Before PS matching analysis significant survival benefits from POAC were not recognized for recurrence-free survival (Hazard ratio=0.76, 95%CI; 0.40-1.45, p=0.41) or cancer-specific survival (Hazard ratio=0.52, 95%CI; 0.22-1.19, p=0.12). After PS matching analysis significant survival benefits from POAC were not recognized for recurrence-free survival (Hazard ratio=0.55, 95%CI; 0.23-1.23, p=0.15) or cancer-specific survival (Hazard ratio=0.46, 95%CI; 0.16-1.18, p=0.11).Conclusion: The one-to-one pair PS matching successfully balanced the clinicopathological factors between the patients with and without POAC. The PS matching analysis demonstrated no significant difference in survival in the patients with stage II colon cancer. |
doi_str_mv | 10.14789/jmj.62.463 |
format | Article |
fullrecord | <record><control><sourceid>jstage_cross</sourceid><recordid>TN_cdi_crossref_primary_10_14789_jmj_62_463</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>article_jmj_62_6_62_463_article_char_en</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4093-12196952d19c3b459473ea7aa49142cee02c19dcf9ab3a18d084f9f962e6fd3f3</originalsourceid><addsrcrecordid>eNo9UF1L7DAQLXIFRX3yD-RdujdfmzYPl8tS_FhQFFafQ0ynbkqbLEla2H9v1lVfZobDmXNmTlFcE7wgvKrl337sF4IuuGAnxTkldV1SQsWfr7kqZcWqs-Iqxh5jTCWWRPDzYnrxMfkdBJ3sDGjV9tOsXULNFkafthnf7dF63AU_Q0SbKcx21gOyDm2S_gC0XqPGD96hRjsDAf1HK_QSsqCLNu3RxvgA6Ekns7XuA62cHvbRxsvitNNDhKvvflG83d2-Ng_l4_P9ulk9loZjyUpCiRRySVsiDXvnS8krBrrSmkvCqQHA1BDZmk7qd6ZJ3eKad7KTgoLoWtaxi-LmqGuCjzFAp3bBjjrsFcHqKzSVQ1OCqhxaZt8f2SO01uj81WAdqN5PId8dVdeSfnIJFMVEKIwFxYe2VDhv51IRRjLID0r_jkp9PKT066pDsmaAH1Px7fyLm60OChz7BCp_jXQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Postoperative Adjuvant Chemotherapy Improves Survival in Stage II Colon Cancer ? A Propensity Score Matching Analysis</title><source>J-STAGE Free</source><creator>SUGIMOTO, KIICHI ; SAKAMOTO, KAZUHIRO ; NIWA, KOICHIRO ; ISHIYAMA, SHUN ; KAMIYAMA, HIROHIKO ; KOMIYAMA, HIROMITSU ; TAKAHASHI, MAKOTO ; KOJIMA, YUTAKA ; GOTO, MICHITOSHI ; TOMIKI, YUICHI</creator><creatorcontrib>SUGIMOTO, KIICHI ; SAKAMOTO, KAZUHIRO ; NIWA, KOICHIRO ; ISHIYAMA, SHUN ; KAMIYAMA, HIROHIKO ; KOMIYAMA, HIROMITSU ; TAKAHASHI, MAKOTO ; KOJIMA, YUTAKA ; GOTO, MICHITOSHI ; TOMIKI, YUICHI ; Juntendo University Faculty of Medicine ; Department of Coloproctological Surgery</creatorcontrib><description>Objective: The use of postoperative adjuvant chemotherapy (POAC) after surgery for patients with stage II colon cancer remains controversial. The current study was conducted to investigate the effectiveness of POAC using propensity score (PS) matching analysis based on prognostic factors.Materials: Two hundred and nineteen patients with stage II colon cancer who underwent surgery with curative intent between 1995 and 2005 were enrolled.Methods: PS matching analysis was used to adjust for differences in clinicopathological severity between the patients with and without POAC.Results: Before PS matching analysis significant survival benefits from POAC were not recognized for recurrence-free survival (Hazard ratio=0.76, 95%CI; 0.40-1.45, p=0.41) or cancer-specific survival (Hazard ratio=0.52, 95%CI; 0.22-1.19, p=0.12). After PS matching analysis significant survival benefits from POAC were not recognized for recurrence-free survival (Hazard ratio=0.55, 95%CI; 0.23-1.23, p=0.15) or cancer-specific survival (Hazard ratio=0.46, 95%CI; 0.16-1.18, p=0.11).Conclusion: The one-to-one pair PS matching successfully balanced the clinicopathological factors between the patients with and without POAC. The PS matching analysis demonstrated no significant difference in survival in the patients with stage II colon cancer.</description><identifier>ISSN: 2187-9737</identifier><identifier>EISSN: 2188-2126</identifier><identifier>DOI: 10.14789/jmj.62.463</identifier><language>eng</language><publisher>The Juntendo Medical Society</publisher><subject>5-FU ; postoperative adjuvant chemotherapy ; prognostic factor ; propensity score matching analysis ; stage II colon cancer</subject><ispartof>Juntendo Medical Journal, 2016, Vol.62(6), pp.463-471</ispartof><rights>2016 The Juntendo Medical Society. This is an open access article distributed under the terms of Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original source is properly credited.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4093-12196952d19c3b459473ea7aa49142cee02c19dcf9ab3a18d084f9f962e6fd3f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1883,4024,27923,27924,27925</link.rule.ids></links><search><creatorcontrib>SUGIMOTO, KIICHI</creatorcontrib><creatorcontrib>SAKAMOTO, KAZUHIRO</creatorcontrib><creatorcontrib>NIWA, KOICHIRO</creatorcontrib><creatorcontrib>ISHIYAMA, SHUN</creatorcontrib><creatorcontrib>KAMIYAMA, HIROHIKO</creatorcontrib><creatorcontrib>KOMIYAMA, HIROMITSU</creatorcontrib><creatorcontrib>TAKAHASHI, MAKOTO</creatorcontrib><creatorcontrib>KOJIMA, YUTAKA</creatorcontrib><creatorcontrib>GOTO, MICHITOSHI</creatorcontrib><creatorcontrib>TOMIKI, YUICHI</creatorcontrib><creatorcontrib>Juntendo University Faculty of Medicine</creatorcontrib><creatorcontrib>Department of Coloproctological Surgery</creatorcontrib><title>Postoperative Adjuvant Chemotherapy Improves Survival in Stage II Colon Cancer ? A Propensity Score Matching Analysis</title><title>Juntendo Iji Zasshi = Juntendo Medical Journal</title><addtitle>Juntendo Medical Journal</addtitle><description>Objective: The use of postoperative adjuvant chemotherapy (POAC) after surgery for patients with stage II colon cancer remains controversial. The current study was conducted to investigate the effectiveness of POAC using propensity score (PS) matching analysis based on prognostic factors.Materials: Two hundred and nineteen patients with stage II colon cancer who underwent surgery with curative intent between 1995 and 2005 were enrolled.Methods: PS matching analysis was used to adjust for differences in clinicopathological severity between the patients with and without POAC.Results: Before PS matching analysis significant survival benefits from POAC were not recognized for recurrence-free survival (Hazard ratio=0.76, 95%CI; 0.40-1.45, p=0.41) or cancer-specific survival (Hazard ratio=0.52, 95%CI; 0.22-1.19, p=0.12). After PS matching analysis significant survival benefits from POAC were not recognized for recurrence-free survival (Hazard ratio=0.55, 95%CI; 0.23-1.23, p=0.15) or cancer-specific survival (Hazard ratio=0.46, 95%CI; 0.16-1.18, p=0.11).Conclusion: The one-to-one pair PS matching successfully balanced the clinicopathological factors between the patients with and without POAC. The PS matching analysis demonstrated no significant difference in survival in the patients with stage II colon cancer.</description><subject>5-FU</subject><subject>postoperative adjuvant chemotherapy</subject><subject>prognostic factor</subject><subject>propensity score matching analysis</subject><subject>stage II colon cancer</subject><issn>2187-9737</issn><issn>2188-2126</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNo9UF1L7DAQLXIFRX3yD-RdujdfmzYPl8tS_FhQFFafQ0ynbkqbLEla2H9v1lVfZobDmXNmTlFcE7wgvKrl337sF4IuuGAnxTkldV1SQsWfr7kqZcWqs-Iqxh5jTCWWRPDzYnrxMfkdBJ3sDGjV9tOsXULNFkafthnf7dF63AU_Q0SbKcx21gOyDm2S_gC0XqPGD96hRjsDAf1HK_QSsqCLNu3RxvgA6Ekns7XuA62cHvbRxsvitNNDhKvvflG83d2-Ng_l4_P9ulk9loZjyUpCiRRySVsiDXvnS8krBrrSmkvCqQHA1BDZmk7qd6ZJ3eKad7KTgoLoWtaxi-LmqGuCjzFAp3bBjjrsFcHqKzSVQ1OCqhxaZt8f2SO01uj81WAdqN5PId8dVdeSfnIJFMVEKIwFxYe2VDhv51IRRjLID0r_jkp9PKT066pDsmaAH1Px7fyLm60OChz7BCp_jXQ</recordid><startdate>2016</startdate><enddate>2016</enddate><creator>SUGIMOTO, KIICHI</creator><creator>SAKAMOTO, KAZUHIRO</creator><creator>NIWA, KOICHIRO</creator><creator>ISHIYAMA, SHUN</creator><creator>KAMIYAMA, HIROHIKO</creator><creator>KOMIYAMA, HIROMITSU</creator><creator>TAKAHASHI, MAKOTO</creator><creator>KOJIMA, YUTAKA</creator><creator>GOTO, MICHITOSHI</creator><creator>TOMIKI, YUICHI</creator><general>The Juntendo Medical Society</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>2016</creationdate><title>Postoperative Adjuvant Chemotherapy Improves Survival in Stage II Colon Cancer ? A Propensity Score Matching Analysis</title><author>SUGIMOTO, KIICHI ; SAKAMOTO, KAZUHIRO ; NIWA, KOICHIRO ; ISHIYAMA, SHUN ; KAMIYAMA, HIROHIKO ; KOMIYAMA, HIROMITSU ; TAKAHASHI, MAKOTO ; KOJIMA, YUTAKA ; GOTO, MICHITOSHI ; TOMIKI, YUICHI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4093-12196952d19c3b459473ea7aa49142cee02c19dcf9ab3a18d084f9f962e6fd3f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>5-FU</topic><topic>postoperative adjuvant chemotherapy</topic><topic>prognostic factor</topic><topic>propensity score matching analysis</topic><topic>stage II colon cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SUGIMOTO, KIICHI</creatorcontrib><creatorcontrib>SAKAMOTO, KAZUHIRO</creatorcontrib><creatorcontrib>NIWA, KOICHIRO</creatorcontrib><creatorcontrib>ISHIYAMA, SHUN</creatorcontrib><creatorcontrib>KAMIYAMA, HIROHIKO</creatorcontrib><creatorcontrib>KOMIYAMA, HIROMITSU</creatorcontrib><creatorcontrib>TAKAHASHI, MAKOTO</creatorcontrib><creatorcontrib>KOJIMA, YUTAKA</creatorcontrib><creatorcontrib>GOTO, MICHITOSHI</creatorcontrib><creatorcontrib>TOMIKI, YUICHI</creatorcontrib><creatorcontrib>Juntendo University Faculty of Medicine</creatorcontrib><creatorcontrib>Department of Coloproctological Surgery</creatorcontrib><collection>CrossRef</collection><jtitle>Juntendo Iji Zasshi = Juntendo Medical Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SUGIMOTO, KIICHI</au><au>SAKAMOTO, KAZUHIRO</au><au>NIWA, KOICHIRO</au><au>ISHIYAMA, SHUN</au><au>KAMIYAMA, HIROHIKO</au><au>KOMIYAMA, HIROMITSU</au><au>TAKAHASHI, MAKOTO</au><au>KOJIMA, YUTAKA</au><au>GOTO, MICHITOSHI</au><au>TOMIKI, YUICHI</au><aucorp>Juntendo University Faculty of Medicine</aucorp><aucorp>Department of Coloproctological Surgery</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Postoperative Adjuvant Chemotherapy Improves Survival in Stage II Colon Cancer ? A Propensity Score Matching Analysis</atitle><jtitle>Juntendo Iji Zasshi = Juntendo Medical Journal</jtitle><addtitle>Juntendo Medical Journal</addtitle><date>2016</date><risdate>2016</risdate><volume>62</volume><issue>6</issue><spage>463</spage><epage>471</epage><pages>463-471</pages><issn>2187-9737</issn><eissn>2188-2126</eissn><abstract>Objective: The use of postoperative adjuvant chemotherapy (POAC) after surgery for patients with stage II colon cancer remains controversial. The current study was conducted to investigate the effectiveness of POAC using propensity score (PS) matching analysis based on prognostic factors.Materials: Two hundred and nineteen patients with stage II colon cancer who underwent surgery with curative intent between 1995 and 2005 were enrolled.Methods: PS matching analysis was used to adjust for differences in clinicopathological severity between the patients with and without POAC.Results: Before PS matching analysis significant survival benefits from POAC were not recognized for recurrence-free survival (Hazard ratio=0.76, 95%CI; 0.40-1.45, p=0.41) or cancer-specific survival (Hazard ratio=0.52, 95%CI; 0.22-1.19, p=0.12). After PS matching analysis significant survival benefits from POAC were not recognized for recurrence-free survival (Hazard ratio=0.55, 95%CI; 0.23-1.23, p=0.15) or cancer-specific survival (Hazard ratio=0.46, 95%CI; 0.16-1.18, p=0.11).Conclusion: The one-to-one pair PS matching successfully balanced the clinicopathological factors between the patients with and without POAC. The PS matching analysis demonstrated no significant difference in survival in the patients with stage II colon cancer.</abstract><pub>The Juntendo Medical Society</pub><doi>10.14789/jmj.62.463</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2187-9737 |
ispartof | Juntendo Medical Journal, 2016, Vol.62(6), pp.463-471 |
issn | 2187-9737 2188-2126 |
language | eng |
recordid | cdi_crossref_primary_10_14789_jmj_62_463 |
source | J-STAGE Free |
subjects | 5-FU postoperative adjuvant chemotherapy prognostic factor propensity score matching analysis stage II colon cancer |
title | Postoperative Adjuvant Chemotherapy Improves Survival in Stage II Colon Cancer ? A Propensity Score Matching Analysis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T18%3A08%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstage_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Postoperative%20Adjuvant%20Chemotherapy%20Improves%20Survival%20in%20Stage%20II%20Colon%20Cancer%20?%20A%20Propensity%20Score%20Matching%20Analysis&rft.jtitle=Juntendo%20Iji%20Zasshi%20=%20Juntendo%20Medical%20Journal&rft.au=SUGIMOTO,%20KIICHI&rft.aucorp=Juntendo%20University%20Faculty%20of%20Medicine&rft.date=2016&rft.volume=62&rft.issue=6&rft.spage=463&rft.epage=471&rft.pages=463-471&rft.issn=2187-9737&rft.eissn=2188-2126&rft_id=info:doi/10.14789/jmj.62.463&rft_dat=%3Cjstage_cross%3Earticle_jmj_62_6_62_463_article_char_en%3C/jstage_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |